A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
NCT04773522
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
Talquetamab
Sponsor
Janssen Pharmaceutical K.K.